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Abstract
In Parkinson's disease, dopamine-containing nigrostriatal neurons undergo profound degeneration. Tyrosine hydroxylase (TH) is the rate-limiting enzyme in dopamine biosynthesis. TH increases in vitro formation of reactive oxygen species, and
previous animal studies have reported links between cytosolic dopamine build-up
and oxidative stress. To examine effects of increased TH activity in catecholaminergic neurons in vivo, we generated TH-over-expressing mice (TH-HI) using a BAC-
transgenic approach that results in over-expression of TH with endogenous patterns
of expression. The transgenic mice were characterized by western blot, qPCR, and
immunohistochemistry. Tissue contents of dopamine, its metabolites, and markers
of oxidative stress were evaluated. TH-HI mice had a 3-fold increase in total and

Abbreviations: AADC, aromatic amino acid decarboxylase; ALDH, aldehyde dehydrogenase; BAC, bacterial artificial chromosome; BCA, bicinchoninic acid; BME, beta-mercaptoethanol;
CAMKII, calmodulin-s timulated protein kinase II; CT, cycle threshold; Cys-DA, cysteinylated dopamine; Cys-DOPA, cysteinylated dihydroxyphenylalanine; DA, dopamine; DA-Q ,
dopamine quinone; DAT, dopamine transporter; DHPG, dihydroxyphenylglycine; DOPAC, 3,4-dihydroxyphenylacetic acid; DOPAL, 3,4-dihydroxyphenylacetaldehyde; DOPA-Q ,
dihydroxyphenylalanine quinone; ERK, extracellular signal-related protein kinases; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; GSH, glutathione; H2O2, hydrogen peroxide;
HPLC, high performance liquid chromatography; LB, lysogeny broth; L-DOPA, L-3 ,4-dihydroxyphenylalanine; MAO, monoamine oxidase A; MES, 2[N-morpholino] ethanesulphonic acid;
MOPS, 3-(N-morpholino)propanesulfonic acid; MPA, metaphosphoric acid; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; NA, noradrenaline; Na+/K+-ATPase, sodium-
potassium pump; NET, norepinephrine (or noradrenaline) transporter; PBS, phosphate buffered saline; PCR, polymerase chain reaction; PKA, cyclic AMP-dependent protein kinase A;
Pkg, cGMP-dependent protein kinase (or protein kinase G); PP2A, protein phosphatase 2A; PVDF, polyvinylidene difluoride; qPCR, quantitative polymerase chain reaction; RIPA,
radioimmunoprecipitation assay; ROS, reactive oxygen species; SDS, sodium dodecyl sulfate; Ser-, serine; TEAM, triethanolamine; Tfrc, transferrin receptor; TH, tyrosine hydroxylase;
VMAT2, vesicular monoamine transporter-2 .
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phosphorylated TH levels and an increased rate of dopamine synthesis. Coincident
with elevated dopamine turnover, TH-HI mice showed increased striatal production
of H2O2 and reduced glutathione levels. In addition, TH-HI mice had elevated striatal levels of the neurotoxic dopamine metabolites 3,4-dihydroxyphenylacetaldehyde
and 5-S-cysteinyl-dopamine and were more susceptible than wild-t ype mice to the
effects of amphetamine and methamphetamine. These results demonstrate that increased TH alone is sufficient to produce oxidative stress in vivo, build up autotoxic
dopamine metabolites, and augment toxicity.
KEYWORDS

amphetamine, DOPAL, dopamine, oxidative stress, tyrosine hydroxylase

1 | I NTRO D U C TI O N

kinases I and II (ERKI and II) is also believed to directly promote enzymatic activity, possibly with a greater role in somatodendritic

The neurochemical hallmark of Parkinson's disease is depletion of

compartments of dopaminergic cells (Salvatore, 2014; Salvatore

the catecholamine dopamine in the nigrostriatal system, particu-

et al. 2016, 2018). In contrast, phosphorylation of Ser19, primarily me-

larly in the putamen (Kish et al. 1988). By the time the characteris-

diated by calmodulin-stimulated protein kinase II (CaMK II), is believed

tic motor symptoms manifest clinically, it is likely that a substantial

to facilitate enzymatic activity indirectly by inducing a conformational

proportion of striatal dopaminergic terminals have already been lost

change and increasing phosphorylation at Ser40 and Ser31 (Haycock

(Dalle-Donne et al. 2008). The dropout of midbrain substantia nigra

et al. 1998; Lindgren et al. 2000). By releasing the enzyme from end-

neurons seems often to be preceded by comparable degeneration of

point inhibition and returning it to its activate state, phosphorylation

noradrenergic neurons in the pontine locus coeruleus (Del Tredici &

of TH plays a direct role in the rate of catecholamine synthesis and

Braak, 2013), which might contribute to pre-motor symptoms (Braak

bioavailability (Daubner et al. 2011; Dunkley et al. 2004).

et al. 2003; Darvas et al. 2014; Fahn, 2003).

Protein phosphatase 2A (PP2A) is the main phosphatase respon-

Oxidative stress is widely recognized as a contributor to the

sible for dephosphorylating TH and regulating its activity (Haavik

pathogenesis of idiopathic Parkinson's disease; however, why

et al. 1989; Peng et al. 2005). In addition, α-synuclein also nega-

catecholaminergic neurons are especially susceptible remains

tively regulates the activity of TH, directly and indirectly, by activat-

incompletely understood. Many factors may underlie the prefer-

ing PP2A (Hua et al. 2015; Liu et al. 2008; Peng et al. 2005; Perez

ential vulnerability of catecholamine neurons, including patterns

et al. 2002; Qu et al. 2018). However, α-synuclein phosphorylated

of alpha(α)-synuclein aggregation and spread; mitochondrial dys-

at Ser129—a major constituent of insoluble α-synuclein aggregates

function; an extensive axonal arbor, particularly characteristic of

(Arawaka et al. 2017; Walker et al. 2013; Zhou et al. 2011)—has a

substantia nigra cells; and cell- or region-specific characteristics of

limited ability to inhibit TH activity (Lou et al. 2010; Wu et al. 2011)

cell signalling, including an increasing dependency on calcium chan-

and has been linked to dopamine dysregulation (Alerte et al. 2008).

nels, which can increase mitochondrial stress (Blesa et al. 2015;

Increased levels of Ser129 phosphorylation have been associated

Bolam & Pissadaki, 2012; Puspita et al. 2017; Ricke et al. 2020;

with diminished PP2A, in part because PP2A is also responsible for

Surmeier, 2007, 2018; Surmeier et al. 2017). Another specific source

dephosphorylating α-synuclein (Liu et al. 2015; Park et al. 2016).

of vulnerability may relate to autotoxicity resulting from metabolites

Recent studies have shown that the relationship between reduced

of the catecholamines (Goldstein et al. 2014; Masato et al. 2019;

PP2A and α-synuclein Ser129 phosphorylation is one of positive

Miyazaki & Asanuma, 2008). Testing this notion in vivo, however,

feedback, with aggregated or phosphorylated α-synuclein further

has been a difficult challenge that few studies have tackled.

reducing PP2A function (Chen et al. 2016; Liu et al. 2015; Tian

The rate-limiting enzyme in catecholamine biosynthesis is tyro-

et al. 2018) and TH regulation (Farrell et al. 2014).

sine hydroxylase (TH). During catecholamine synthesis, small amounts

Studies in transgenic models show that increased TH activity and

of reactive oxygen species (ROS) are generated (Adams et al. 1997;

elevated ROS can result from diminished regulation placed on the

Haavik et al. 1997; Kostyn et al. 2020). Activity of TH is modulated

enzyme. In Drosophilia and C. elegans, dysfunctional α-synuclein has

by phosphorylation of 3 main serine (Ser-) residues on its amino

been reported to increase levels of phosphorylated TH and elevate

terminus: Ser19, Ser31, and Ser40 (Daubner et al. 2011; Dunkley &

dopamine levels, ultimately leading to oxidative stress and neuro-

Dickson, 2019). The predominant source of TH activation is phos-

degeneration (Locke et al. 2008; Park et al. 2007). Similarly, mice

phorylation at Ser40, chiefly mediated by cyclic AMP-dependent

with mutated or aggregated α-synuclein show increased levels of

protein kinase A (PKA) (Lehmann et al. 2006; Salvatore et al. 2001).

TH activity and behavioural impairment attributed to catecholamine

Phosphorylation of TH at Ser31 by extracellular signal-related protein

dysregulation (Alerte et al. 2008; Farrell et al. 2014). Therefore,
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increased activity of TH, in concert with other changes, could pres-

our model is the first to achieve functional over-expression of TH

ent a source of oxidative stress unique to catecholamine neurons

and increased dopamine synthesis that are restricted to endogenous

(Alerte et al. 2008; Chen et al. 2016; Hua et al. 2015; Liu et al. 2015;

catecholaminergic regions.

Lou et al. 2010; Park et al. 2016; Peng et al. 2005).
ROS resulting from the accumulation of cytosolic dopamine may
represent an additional source of oxidative stress in cells with increased

2 | M ATE R I A L S A N D M E TH O DS

synthetic activity (Chen et al. 2008; Stansley & Yamamoto, 2013).
Ordinarily, cytosolic dopamine levels are kept very low because of avid

Experiments were conducted in adult mice (male and female),

uptake into vesicles via the type 2 vesicular monoamine transporter

3–5 months of age (for experimental design, see Figure 1). Mice were

(VMAT2). Unsequestered dopamine undergoes metabolism by mono-

housed on a 12-hr light–dark cycle, with food and water provided

amine oxidase (MAO), which generates hydrogen peroxide (H2O2)

ad libitum. No randomization was performed to allocate subjects in

as well as the catecholaldehyde 3,4-dihydroxyphenylacetaldehyde

the study. Mice within a genotype were allocated arbitrarily to the

(DOPAL), a highly reactive intermediate metabolite (Goldstein

experimental groups such that each group contained comparable

et al. 2016; Graham, 1978; Hermida-Ameijeiras et al. 2004).

numbers of males and females. Group sizes were based on previ-

DOPAL is metabolized by aldehyde dehydrogenase (ALDH) to form

ous work (Masoud et al. 2015; Salahpour et al. 2008). In most cases,

3,4-dihydroxyphenylacetic acid (DOPAC), which rapidly exits the cells

the experimenter was not aware of the genotype of the mice until

(Lamensdorf et al. 2000).

the point of statistical analysis. Western blots were an exception, as

According to the catecholaldehyde hypothesis, DOPAL can play
a role in the pathogenesis of Parkinson's disease (Casida et al. 2014;

these were loaded such that samples within a genotype or treatment
group neighboured each other on the blot.

Fitzmaurice et al. 2013; Goldstein et al. 2016; Panneton et al. 2010;

A total of 332 mice were used for this study, inclusive of all ex-

Wey et al. 2012), especially via modifications of cytosolic proteins

perimental groups and genotypes. Effort was made to minimize anx-

such as α-synuclein (Jinsmaa et al. ,2018, 2020). DOPAL has been

iety and suffering by habituating animals to behavioural suites, and

shown to promote oligomerization of α-synuclein by covalent mod-

ensuring that mice were accustomed to the experimenters' touch

ifications of lysine residues (Burke et al. 2008; Follmer et al. 2015),

and scent.

and DOPAL-induced α-synuclein oligomers impede vesicular func-

Anaesthesia (avertin) was verified by the toe-pinch and eye-

tions (Plotegher et al. 2017), potentially setting the stage for a vicious

brush methods, and by observing a depression in respiratory rate

pathophysiological cycle. Moreover, in the setting of divalent metal

(i.e. that breathing had appreciably slowed). Shortly in advance

cations, DOPAL can react with H2O2 to produce extremely toxic

of experiments requiring anaesthesia, a 20-mL stock volume

hydroxyl radicals (Li et al. 2001; Werner-Allen et al. 2017). Finally,

of avertin was prepared: in a 1.5-mL Eppendorf tube, 0.5 ml of

DOPAL spontaneously oxidizes to DOPAL-quinone, in the process

2-methyl-2-butanol (Sigma, cat. no. 152463) was added to 0.25 g of

generating superoxide radicals (Anderson et al. 2011; Werner-Allen

2,2,2-tribromoethanol (Sigma, cat. no. T48402). The solution was

et al. 2017).

heated slightly (37–4 0℃) and mixed well. The solution was added

Cytosolic dopamine can also undergo spontaneous oxidation

slowly to sterile ddH2O, and topped to a total volume of 20 ml; the

to produce dopamine-quinone and then a variety of potentially

stock solution (1.25 g/ml) was then sterilized through a 0.22-μm

toxic downstream products such as aminochrome, salsolinols,

filter. Aliquots were stored in the dark at 4℃, and prepared fresh

and 5-S-cysteinyl-dopamine (Cys-DA) (Chen et al. 2008; Hastings

weekly; aliquots were thawed in the dark before use. Mice were in-

et al. 1996; Miyazaki & Asanuma, 2008; Montine et al. 1997; Segura-

jected intraperitoneally at a dose of 200 mg/kg.

Aguilar et al. 2014; Stansley & Yamamoto, 2013; Storch et al. 2002).

Euthanasia was performed with the guidance and approval of

Dopamine can form quinoprotein adducts with α-synuclein (Bisaglia

the Animal Care Committee. Procedures conformed to the recom-

et al. 2010), although in this regard DOPAL is more potent (Jinsmaa

mendations of the Canadian Council on Animal Care, with proto-

et al. 2020).

cols reviewed and approved by the University of Toronto Faculty of

Based on previous studies, increased activity of TH has the capacity to facilitate the development of oxidative stress via two main pro-

Medicine and Pharmacy Animal Care Committee (protocol number
20011466).

cesses. First, ROS can be generated during catecholamine synthesis,
previously shown in vitro; and second, elevated synthesis may result
in increased levels of cytosolic dopamine, which promotes oxidative
stress through metabolic and spontaneous oxidation. To evaluate

2.1 | Production of TH-over-expressing mice using
BAC transgenesis

the specific effect of elevated TH in vivo, we developed a novel line
of transgenic mice over-expressing functional TH. We hypothesized

Mice over-expressing TH were created by bacterial artificial chro-

that an increase in the enzymatic activity of TH would increase oxi-

mosome (BAC) transgenesis using an artificial chromosome that

dative stress and augment endogenous levels of both enzymatic and

contains the murine Th locus as well as approximately 90 kb of

spontaneous oxidation products of dopamine. TH over-expressing

genomic DNA upstream and downstream of the gene (RP23-

mice have been produced previously (Kaneda et al. 1991); however,

350E13, Genome Sciences), using previously described methods

|

VECCHIO et al.

963

(RP23-350E13)

preparation of bacterial artifical chromosome
Th ( 7.19 Kb)
103 Kb

90 Kb

Pronuclear injection and implantation
into pseudopregnant female

4 transgenic pups born

Presence of Th transgene determined for all pups
One mouse with 4 additional copies of Th
chosen as colony founder to ‘TH-HI’ line

colony established

Aged 3 - 5 months

characterisation of TH-HI mice
(gene and protein analyses)

dopamine, metabolites,
and markers of oxidative stress

amphetamine and
methamphetamine challenges

total TH genomic copy number:
WT=5, TH-HI=5
TH mRNA: WT=8, TH-HI=7

tissue content:
striatal L-DOPA: WT=7, TH-HI=7

unstimulated locomotor behaviour, 240 min:
WT=12, TH-HI=11

striatal DA, DOPAC, DOPAL, Cys-DOPA
and Cys-DA: WT=10, TH-HI=9

amphetamine challenge (saline, 2.0 mg/kg
or 3.0 mg/kg): n=6-13 per genotype, per
treatment group

protein analysis:
midbrain and striatal TH: WT=6, TH-HI=6
midbrain and striatal DAT: WT=6, TH-HI=6
locus coeruleus TH: WT=4, TH-HI=5
striatal phosphoTH ser19: WT=6, TH-HI=6
striatal phosphoTH ser31: WT=4, TH-HI=6
striatal phosphoTH ser40: WT=6, TH-HI=6
striatal VMAT2: WT=5, TH-HI=6, VMAT2-kd=2
peripheral TH: WT=6, TH-HI=5

cardiac DA, DOPAC, NA, DHPG, DOPAL,
Cys-DA: WT=12, TH-HI=8
striatal glutathione: WT=14,TH-HI=14,
reserpine-treated WT=7
striatal H2O2: WT=8, TH-HI=9

immunohistochemistry of TH in midbrain,
striatum and locus coeruleus: n=4 to 6
per region, per genotype
(representative samples shown)

3.0 mg/kg amphetamine with saline or
NSD-1015 pretreatment: n=5-8 per genotype,
per condition
D1/D2 receptor analyses: WT=4, TH-HI=4
methamphetamine challenge (saline,
5.0 mg/kg, or 10.0 mg/kg methampehtamine):
n= 5-7 per genotype, per treatment group

F I G U R E 1 Experimental design. A bacterial artificial chromosome (BAC) carrying the tyrosine hydroxylase gene (Th, 7.19Kb) as well as
103 Kb and 90 Kb of genomic DNA upstream and downstream of the gene was selected (RP23-350E13). Bacterial colonies were grown
on a chloramphenicol-spiked lysogeny broth (LB) agar plate, and single colonies were randomly selected for growth in liquid LB media
(12.5 µg/ml chloramphenicol). The colonies were verified by PCR-based genotyping using primers that amplify a sequence overlapping the
BAC vector and the Th gene. The BAC DNA was isolated and purified using a NucleoBond BAC 100 preparation kit. After resuspension,
the DNA preparation was inserted into fertilized oocytes using pronuclear microinjection, then implanted into a pseudopregnant mother.
Of the first litter born to her, there were four pups identified as transgenic. A pup that had six total copies of the Th gene (i.e. 4 transgenic
copies) was used as the founder to a novel line of TH over-expressing mice, 'TH-HI'. From this mouse, a colony was established. Adult mice
approximately 3–5 months of age were used for further studies. These experiments fell into three main groups: those that characterized the
novel TH-HI mouse line (gene, mRNA and protein analyses); those that analysed tissue content of dopamine, its metabolites, and markers of
oxidative stress; and those that assessed the locomotor response to compounds known to affect the dopaminergic system, amphetamine,
and methamphetamine. The number of mice (n) used for each experiment is indicated. Cys-DOPA, 5-S-cysteinyldopa; Cys-DA, 5-S-
cysteinyldopamine; D1/D2, dopamine receptors type 1 and 2; DA, dopamine; DHPG, 3,4-dihydroxyphenylethylene glycol; DAT, dopamine
transporter; DOPAC, 3,4-dihydroxyphenylacetic acid; DOPAL, 3,4-dihydroxyphenylacetaldehyde; L-DOPA, l-3,4-dihydroxyphenylalanine;
n, number of mice; NA, noradrenaline; TH, tyrosine hydroxylase; TH-HI, transgenic mice over-expressing tyrosine hydroxylase; VMAT2,
vesicular monoamine transporter 2; VMAT-kd, VMAT2-knockdown mice; WT, wild-t ype mice
(Lohr et al. 2014; Salahpour et al. 2008). Because BACs often contain

were grown on a chloramphenicol-spiked lysogeny broth (LB) agar

the endogenous promotor for a gene of interest, gene expression is

plate, and single colonies were randomly selected for growth in

restricted to regions that endogenously express it. Bacterial colonies

liquid LB media (12.5 µg/ml chloramphenicol). The colonies were
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verified by PCR-based genotyping using primers that amplify a

cells within the dissected area, Th mRNA levels (forward primer:

sequence overlapping the BAC vector and the Th gene (forward,

5'-cgggcttctctgaccaggcg; reverse primer: 5'-tggggaattggctcaccctgct)

5’-gaaggctctcaagggcatc; reverse, 5′-acaggtcaggctctcaggtc).

were presented as a ratio of the dopamine transporter (DAT),

The BAC DNA was isolated using a NucleoBond BAC 100 prepa-

Slc6a3, mRNA levels (forward primer: 5'-ggcctgggcctcaacgacac; re-

ration kit (Macherey-Nagel, cat no. 740579) and resuspended in in-

verse primer: 5'-ggtgcagcacaccacgtccaa). Phosphoglycerate kinase

jection buffer (spermine, 0.03 mM; spermidine, 0.07 mM). Pronuclear

1 (Pgk1; forward primer:5'-ggcctttcgacctcacggtgt; reverse primer:

microinjections were performed at the Emory University Transgenic

5'-gtccaccctcatcacgacccg) was used as the reference gene, and relative

Facility. Transgenic positive pups were identified by PCR-based ge-

quantification of both targets was obtained using the 2-∆ ∆CT method.

notyping (5’-aggagctgactgggttgaag; reverse, 5′-tcgtggcctgttgtgagtag);
again, primer sequences overlapped the vector and gene sequences,
thereby differentiating transgenic Th from native Th. Of the F1

2.3 | Western blotting

generation, a mouse determined by qPCR to possess 6 total copies of genomic Th was used as a founder for a transgenic high copy
line, "TH-HI." Transgenic mice were maintained on a C57Bl/6J

2.3.1 | Total TH and DAT in the central and
peripheral systems

background.
Western blots were performed to quantify TH and DAT protein

2.2 | Determination of gene copy number and total
Th mRNA levels

expression in the dopaminergic nigrostriatal pathway, using the
sodium-potassium pump (Na+/K+-ATPase) as a loading control. The
midbrain (substantia nigra) and striatum were dissected from freshly
harvested brains, flash-frozen, and mechanically homogenized in

2.2.1 | Gene copy number

RIPA buffer [50 mM Tris·HCl, pH 7.4; 150 mM NaCl; 1% Nonidet
P-4 0; 0.5% sodium deoxycholate; 0.1% sodium dodecyl sulphate

Genomic DNA was isolated from tail biopsy following Proteinase K di-

(SDS)] with protease inhibitors (pepstatin A, 5 μg/mL; leupeptin,

gestion and isopropanol precipitation (Ballester et al. 2004; Burkhart

10 μg/mL; aprotinin, 1.5 μg/mL; benzamidine, 0.1 μg/mL; PMSF,

et al. 2002), and cleaned using a chloroform-ammonium acetate wash

0.1 mM). Samples were centrifuged at 21,130 g for 15 min to remove

method. Quantitative PCR (qPCR) was used to determine total allelic

cellular debris and the supernatant was collected. Protein concen-

copy number of Th, inclusive of both native alleles and transgenic cop-

trations were determined using a Pierce bicinchoninic acid (BCA)

ies (Ballester et al. 2004; Shepherd et al. 2009). Amplicons of the Th

assay (Thermo Scientific, cat no. 23225). Samples were prepared

genomic sequence were generated using designed primers (forward:

to the desired loading amount (striatum, 25 μg; midbrain, 60 μg)

5’-caccagtcctgagtttcctatt, reverse: 5’-ctggatcacactccaccatatc) and meas-

in a solution containing 1× SDS sample buffer (4× solution: 3.4 g

ured relative to those of a common reference gene that encodes the

Tris Base, 8.0 g SDS, 40 ml glycerol in 1 L dH2O, pH 6.8), 0.05% β-

transferrin receptor (Tfrc; forward: 5’-cagtcatcagggttgcctaata, reverse:

mercaptoethanol (BME), and RIPA buffer. Preparations were heated

5’-atcacaacctcaccatgtaact). Relative quantification of Th and Tfrc were

to 55℃ for 10 min, separated by 10% SDS/PAGE, and wet-transferred

obtained using the GoTaq® qPCR Master Mix (Promega, cat no. A6002)

to polyvinylidene difluoride (PVDF) membranes (FluoroTrans, Pall,

on the Applied Biosystems 7500 Real-Time PCR System. The PCR pro-

cat no. CA29301-856). Membranes were blocked in Li-COR buffer

tocol used for all reactions was as follows: 2 min at 50℃, 10 min at 95℃,

for 60 min at room temperature and incubated overnight at 4℃ with

40 repeats of 95℃ for 15 s, and 1 min at 60℃. Analysis of gene copy

rat anti-DAT (1:750; Millipore, cat no. MAB369, RRID: AB_2190413)

number was based upon the 2-∆ ∆CT method as previously described

and rabbit anti-Na+/K+-ATPase (1:2000; cat no. 3010, RRID:

(Livak & Schmittgen, 2001; Pfaffl, 2001; Schmittgen & Livak, 2008).

AB_2060983) in the same buffer. After washing, protein bands were
revealed by incubating with the fluorescence-labelled secondary
antibodies donkey anti-rat IRdye 800CW (1:5,000; Rockland, cat

2.2.2 | mRNA

no. 612-732-120, RRID:AB_220173) and goat anti-rabbit AlexaFluor
AF680 (1:5,000; Invitrogen, cat no. A21076, RRID: AB_2535736) for

Reverse-transcriptase qPCR was also used to determine total levels

60 min at room temperature. Without stripping, membranes were

of mRNA on midbrain regions dissected from a 1-mm coronal section

then blocked a second time in 5% non-fat milk and probed with rab-

of brain, which was previously removed and frozen in 2-methybutane

bit anti-TH (1:3,000; Millipore, cat no. AB152, RRID: AB_390204)

over dry ice and stored at −80℃ (Hu et al. 2009); 300 ng of RNA

overnight at 4℃, which was again revealed with goat anti-rabbit

was used to obtain complementary DNA using SuperScript III

AlexaFluor AF680.

Reverse Transcriptase (Invitrogen, cat no. 11752-250) according to

Using similar methods, TH protein levels in both central and

the manufacturer's instructions. As before, quantification of mRNA

peripheral noradrenergic regions were examined. Tissue from the

levels was obtained using the GoTaq® qPCR Master Mix on the

TH-rich locus coeruleus and the adrenal medulla was extracted, pre-

Applied Biosystems 7500 Real-Time PCR System. To ensure that the

pared, and run as described above (loading 60 μg per sample for the

level of Th mRNA was normalized to the volume of dopaminergic

locus coeruleus, 20 μg per sample for the adrenal medulla). PVDF

|
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membranes were probed for rabbit anti-TH as described above.
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Striatal tissues were rapidly dissected and homogenized in lysis

Mouse anti-β-tubulin (1:1,000; Developmental Studies Hybridoma

buffer (50 mM Tris–HCl, pH 7.4; 120 mM NaCl; 1 mM EDTA) con-

Bank, E7) and mouse anti-GAPDH (1:3,000; Sigma, cat no. G8795,

taining protease inhibitors. The homogenate was centrifuged at

RRID:AB_1078991) were used as loading controls for the locus coe-

1,000 g for 10 min (4℃) to remove cellular debris and nuclei, after

ruleus and adrenal medulla (respectively), and revealed with donkey

which supernatant was centrifuged at 40,000 g for 20 min (4℃); the

anti-mouse IRdye 800CW (1:5,000; Rockland, cat no. 610-731-0 02,

pellet was then resuspended in lysis buffer and centrifuged again

RRID: AB_1660943).

under the same conditions. The final pellet was resuspended in assay
buffer (50 mM Tris–HCl (pH 7.4), 120 mM NaCl, 5 mM KCl, 2 mM
CaCl2, and 1 mM MgCl2). Protein concentration of membranes was

2.3.2 | Phosphorylated TH

determined using BCA protein assay.

Levels of TH phosphorylated at serine residues 19, 31, and 40

atal membranes (1.2 μg/μl) was incubated with 50 μl of 16 nM [3H]-

were also measured, as a representation of TH in an active con-

SCH23390, a D1 receptor antagonist, as well as 50 μl of 100 mM

formation. In a separate set of experiments, striatal samples were

ketanserin, a serotonin receptor antagonist, to prevent radioligand

For D1 receptor saturation experiments, 50 μl of prepared stri-

quickly dissected, flash-frozen, and homogenized in RIPA con-

binding to these receptors. The reaction was performed in 200 μl of

taining phosphatase inhibitors (sodium pyrophosphate, 2.5 mM;

assay buffer for 1 hour, at room temperature. In parallel reactions,

β-glycerophosphate, 1.0 mM; sodium fluoride, 50 mM; sodium or-

nonspecific binding was measured using non-radiolabelled flupen-

thovanadate, 1.0 mM), in addition to the protease inhibitors listed

thixol (10 μM), a D1/D2 receptor antagonist. For D2 receptor satu-

above. As before, striatal samples were prepared to the desired

ration experiments, 150 μl of prepared striatal membranes (0.5 μg/

loading amount of 25 μg, run on a 10% SDS/PAGE gel, and trans-

μl) was incubated with 50 μl of [3H]-spiperone (3 nM), a D2 receptor

ferred to PVDF membrane. Membranes were incubated overnight

antagonist. This reaction was performed in 250 μl of assay buffer for

at 4℃ in solutions containing rabbit anti-phosphoTH-Ser19 (1:2000;

2 hours at room temperature; non-specific binding was measured in

PhosphoSolutions, cat no. p1580-19), rabbit anti-phosphoTH-Ser31

parallel using non-radiolabelled haloperidol (6 μM), a D2 antagonist.

(1:1,000; PhosphoSolutions, cat no. p1580-31), or rabbit anti-

All reactions were terminated by filtration over Brandel GF/C

phosphoTH-Ser40 (1:2000; PhosphoSolutions, cat no. p1580-40).

glass fibre filters and washing with cold assay buffer. Filters were

Proteins were revealed using goat anti-rabbit AF680 (1:5,000) before

incubated overnight in high flash point scintillation cocktail (5 ml,

being stripped, and reprobed using mouse anti-TH (1:2,500; Sigma,

Lefko-Fluor). Radioactivity was counted using a liquid scintillation

cat no. T2928, RRID:AB_477569) and mouse anti-GAPDH in 5% non-

counter. Counts of non-specific binding were subtracted from total

fat milk. These were revealed with donkey anti-mouse IRdye 800CW.

binding to obtain specific [3H]-SCH23390 or [3H]-spiperone binding, which corresponds to D1 or D2 binding, respectively, and converted to fmol/mg tissue for final results. The experimenter was

2.3.3 | VMAT2
Levels of VMAT2 were assessed using pre-cast gels and MOPS
(3-(N-morpholino)propanesulfonic acid) buffers, with rabbit anti-

blinded until the point of statistical analyses.

2.5 | Immunohistochemistry

VMAT2 antibody (1:10,000, in-house antibody), as previously described (Cliburn et al. 2017; Lohr et al. 2014). The VMAT2 protein

Adult mice were anaesthetized with avertin (200 mg/kg) prior to

was revealed with goat anti-rabbit 800 (1:5,000; Rockland, cat no.

perfusions, and intracardially perfused with phosphate-buffered

611-131-0 02, RRID: AB_1660973) by incubating for 60 min at room

saline (PBS) at a flow rate of 80 ml/h for 2 min, followed by 4%

temperature, and membranes were reprobed for TH and GAPDH as

paraformaldehyde in PBS for approximately 10 min. The brains

above.

were removed and stored in 4% paraformaldehyde in PBS over-

For all of the above westerns, proteins were visualized using the

night at 4℃, then transferred to a 30% sucrose solution for cryo-

LiCOR Odyssey system. Densitometric analyses were conducted

protection for 48 hr at 4℃. Tissues were blocked in freezing media

using Image Processing and Analysis in Java (ImageJ) software

HistoPrep (Fisher Chemical, cat no. SH75-125D) and cut into

(http://rsb.info.nih.gov/ij/index.html). For full (uncropped) blots, see

40 μm coronal sections using a cryostat (Leica, CM1510). Midbrain

https://osf.io/9q7b5/? view_only=c580d782a77d475984bb35eb4

and striatum sections were immunostained for TH and DAT, using

1738279.

methods previously described (Vecchio et al. 2014); TH and the
noradrenaline transporter (NET) were immunostained in the locus

2.4 | Radioligand binding

coeruleus. Primary antibodies: rabbit anti-TH (1:2000), rat anti-DAT
(1:200), and anti-NET (1:500; MAb Technologies, cat no. NET05-2 ,
RRID:AB_2571639). Secondary antibodies: anti-r abbit AF680

Radioligand binding was used to assess D1 and D2 dopamine recep-

(1:4,000), anti-r at IRdye 800 (1:2000), and anti-mouse IRdye

tor levels in the striatum as previously described (Ghisi et al. 2009).

800CW (1:2000). Slides were scanned using the LiCOR Odyssey

|
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system, with a focus offset of 0.90–1.0 mm. For original scan im-

and cortical samples were then dissected and flash frozen in liquid

ages,

nitrogen. The weight of the frozen tissue was taken, and the tissue

see

https://osf.io/2tqwe/? view_only=c9d0d187221c4ca

989bc93455534b98d.

was homogenized in ice-cold MES buffer (0.4 M 2[N-morpholino]
ethanesulphonic acid, containing 1 mM EDTA; pH 6–7; 10 μL per mg

2.6 | Tissue catechol contents

of tissue). Homogenate was spun at 10,000 g for 15 min at 4℃. The
supernatant was transferred to a clean tube, and deproteinated using
metaphosphoric acid (MPA) and 4 M triethanolamine (TEAM) solu-

Catecholamines (dopamine, noradrenaline), their respective metabo-

tion, as per kit instructions. A subgroup of wild-t ype mice were in-

lites (DOPAC, DHPG), and cysteinylated catechols were measured in

jected with 5 mg/kg of reserpine (injection volume: 0.2 ml/g) 120 min

the striatum and in heart tissue, using methods previously described

prior to dissection, as a positive control of oxidative stress (Spina &

(Casida et al. 2014; Goldstein et al. 2013; Wey et al. 2012). Briefly,

Cohen, 1989). Reserpine is known to irreversibly block VMAT2, lead-

striata were dissected and flash frozen in liquid nitrogen. Frozen tissue

ing the accumulation of cytosolic dopamine (Bernstein et al. 2014; de

samples were homogenized in a mixture of 20:80 of 0.2 M phosphoric

Freitas et al. 2016). In turn, this can lead to increased metabolism, and

acid: 0.2 M acetic acid. The supernate was assayed by batch alumina

enzymatic and spontaneous oxidation, and has been shown to induce

extraction followed by high-performance liquid chromatography

oxidative stress and reduce glutathione in dopaminergic cells (Spina &

(HPLC) with electrochemical detection, using a Spheri-5 RP-18, 5 μm,

Cohen, 1989). Cortical tissue was used as a negative control.

30 × 2.6 mm guard column (PerkinElmer, Part No. 07110013) and C18,
5 µm, 120 Å, 4.6 × 250 mm analytic column (Thomson Instruments,
Part No. BA400-0 46250), on a Waters Model 710B (WISP) automated
sample processor (Waters Associates). The mobile phase consisted of

2.8 | H2O2 assay

13.8 g monobasic sodium phosphate, 28–40 mg octanesulfonic acid,

H2O2 concentrations in striatal samples were measured as per kit in-

50 mg EDTA, and 0–5 ml acetonitrile in 1 L of HPLC-grade water, with

structions (Abcam, cat no. ab102500), using the colorimetric method.

pH adjusted to 3.2–3.3 using 85% phosphoric acid.

Briefly, striata were dissected, homogenized in ice-cold buffer, and

In a separate set of experiments, a single IP injection of the AADC

spun for 5 min at top speed (4℃). Supernatant was immediately de-

inhibitor NSD-1015 (100 mg/kg) was administered to prevent the rapid

proteinated using perchloric acid (PCA, 4 M) and potassium hydroxide

conversation of L-3,4-dihydroxyphenylalanine (L-DOPA) to dopamine

(KOH, 2 M) and samples were spun (15 min, 13,000 g, 4℃), after which

(Jones, Gainetdinov, Jaber, et al., 1998). Mice were sacrificed by cervi-

supernatant was stored at −80℃ until use. In preparation for the

cal dislocation 40 min following the injection, at which time the striata

assay, samples were diluted in assay buffer 1:10, with 50 μl of diluted

were dissected and flash frozen in liquid nitrogen. Unilateral striata were

sample added to 50 μl of reaction mix. Plates were read at OD570 nm.

weighed and homogenized in 40 μL per mg sample of 0.1 M perchlo-

The experimenter was blinded until the point of statistical analyses.

ric acid (HClO4) spiked with both 2,3-dihydroxybenzoic acid (DHBA,
an internal standard) and 100 ng/ml sodium metabisulphite (Caudle
et al. 2007; Moron et al. 2000), and then centrifuged 10,000 g for 10 min
at 4℃. The supernatant was carefully removed and filtered through

2.9 | Locomotor activity and
amphetamine challenge

a 0.22-μm membrane (Ultrafree-MC GVWP filters; Millipore, cat no.
UFC30GV00) by centrifugation at 10,000 g for 2 min at 4℃. Tissue con-

Experiments began at approximately 8:00 a.m., with mice introduced

tent analyses were conducted using an AgAgCl- electrochemical detec-

to the experimental room half an hour prior to beginning.

tor (LC-4C Amperometric Detector; BASi) set at an oxidizing potential

Locomotor activity was measured in automated locomotor activ-

of + 0.75 V, and a Hypersil Gold C18 column (150 × 3 mm, particle size

ity monitors (Accuscan Instruments). Baseline gross locomotor activ-

of 5 μm; Thermo Fisher Scientific). The mobile phase was composed of

ity was measured for 4 hr, with total distance travelled recorded in

5.99 g monobasic sodium phosphate, 200 μM EDTA, 0.684 g sodium

5-min bins (or epochs). In amphetamine-challenge experiments, out-

chloride, 60 mg octyl sodium sulphate, and 95 ml of methanol in 1 L HPLC-

put parameters of total distance travelled and stereotypic behaviours

grade water (pH 2.43). Analytes were quantified against standard curves

were collected in 5-min bins over the course of the test period. Mice

(Sigma, cat no. D9628) (all chemical standards from Sigma, purity >98%).

were placed in the activity monitor chamber (20 cm ×20 cm) and

The experimenter was blinded until the point of statistical analyses.

measured under baseline conditions for 60 min. Following baseline
recording, mice received an injection of saline or 2 mg/kg or 3 mg/kg

2.7 | Glutathione assay

amphetamine (dissolved in 0.9% wv-1 saline) and were observed for
an additional 90 min. All injections were intraperitoneal (IP) at an injection volume of 0.1 ml/g (Salahpour et al. 2008; Vecchio et al. 2014).

Glutathione concentrations in the striatum were measured using

We sought to confirm that augmented amphetamine responses

a glutathione assay kit (Cayman, cat no. 703002), and determined

in TH-HI mice result from increased de novo dopamine synthesis.

using the kinetic method. Brains were removed and quickly rinsed

Wild-t ype and TH-HI mice were separated into two groups each.

in ice-cold PBS to remove blood on the exterior of the brain; striatal

Sixty minutes prior to administration of amphetamine (3.0 mg/kg),
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into pseudo-pregnant females yielding 4 transgenic pups. The total

IP injection of NSD-1015 (100 mg/kg), blocking the synthesis of de

copy number of the Th gene was determined for all pups born to

novo dopamine. As before, mice were allowed to habituate during

the host mothers using quantitative PCR. A pup carrying 6 total

this time. Locomotor activity was recorded for an additional 90 min

copies of the Th gene—2 endogenous alleles and 4 additional copies

following the injection of amphetamine. Due to the potential stress

of Th that resulted from integration of the transgene—was assigned

of the first injection combined with the introduction to the recording

as the founder of the TH-HI line (p ≤ .0001, t-test) (Figure 2a).

chambers, the first 15 min following the first injection were excluded

Commensurate with a 3-fold increase in gene copy number, Th

from analyses of the baseline (pre-amphetamine) period. The experi-

mRNA levels in the midbrain of TH-HI mice were 3 times higher

menter was blinded until the point of statistical analyses.

than that of wild-t ype littermates (measured relative to a commonly used reference gene, Pgk1; p ≤ .0001, t-test) (Figure 2b).

2.10 | Methamphetamine challenge

Transgenic mice did not differ in size or appearance relative to
sex- and age-matched wild-t ype littermates, nor did they have apparent differences in general health. Mice did not have difficulties

Adult wild-t ype and TH-HI mice were randomly assigned to treat-

breeding or delivering pups, and had an average litter size of 5.2

ment groups that would receive 4 injections of 0.9% saline, 5.0 mg/

pups (breeding pairs were retired at 8–12 months of age).

kg or 10 mg/kg of (+)-Methamphetamine HCl (Sigma; dissolved in
0.9% saline). Treatments were administered through a subcutaneous
injection as previously described (Lohr et al. 2015). The first dose
was administered 60 min after baseline core body temperature was
measured using a rectal thermometer. Three additional equivalent

3.2 | TH protein expression is increased in
central and peripheral sites of catecholamine
production in TH-HI mice

doses followed, administered at 2-hr intervals (i.e. 180, 300, and
420 min following the initial injection). Core body temperature was

TH-HI mice showed a 3-fold increase in the optical density of TH

measured at the time of each injection. Mice were killed by rapid

protein in the midbrain (p = .0003, t-test) (Figure 2c, d) and striatum

decapitation 48 hr following the first injection, and the striatum was

(p ≤ .0001, t-test) (Figure 2f, g), revealing that the amount of total

dissected and flash-frozen in liquid nitrogen for protein analyses by

protein translated is proportional to the observed increase in gene

Western blot, using standard methods described above. The experi-

copy number and mRNA. There was no change in the level of DAT

menter was blinded until the point of statistical analyses.

protein between wild-t ype and TH-HI mice (midbrain: Figure 2e,
p = .32, t-test; striatum: Figure 2h, p = .80, t-test).

2.11 | Statistical analyses

Immunostaining revealed that TH protein was expressed in similar
patterns in the midbrain and striatum of wild-t ype and transgenic mice
(Figure 2j, i). No evidence of ectopic expression of TH was detected

All statistical analyses were performed for each group by Student's t-

in the regions that surround the striatum in the forebrain, or the sub-

test, one-way ANOVA, or two-way ANOVA. Post hoc analyses were

stantia nigra and ventral tegmental area in the mesencephalon.

performed using the Bonferroni test, Tukey's test (all pairwise com-

To assess protein expression in the noradrenergic system, we quan-

parisons), or the Dunnett's test, as appropriate. The F-test was used

tified total TH protein in the locus coeruleus. There was an approximate

to verify equal variance. Where there was unequal variance between

3-fold increase in TH optical density, comparable to the increase in TH

two groups analysed by t-test, a Welch's correction was performed. The

observed in dopaminergic regions (p = .0014, t-test) (Figure S1a, b).

Shapiro–Wilk test was used to assess normality of all data. Where this

Immunostaining showed that TH expression patterns in the locus

test revealed that distribution was not normal, t-tests were replaced

coeruleus of transgenic mice mirrored that of wild-t ype littermates,

with non-parametric Mann–Whitney tests. The Grubbs test was used to

again without evidence of ectopic expression (Figure S1c).

identify statistical outliers, which were excluded if found. Significance is

Peripheral expression of TH was measured in the adrenal me-

reported where p < .05. No sample calculations were performed prior

dulla, where it is highly concentrated (de Diego et al. 2008). In

to testing, but sample sizes were based on previous studies. All statisti-

transgenic mice, total TH protein in the adrenal medulla was approxi-

cal testing was carried out using GraphPad Prism version 9.

mately 2.5 times higher than that of wild-t ype littermates (p = .0035,
t-test) (Figure S1d, e), demonstrating successful overproduction of

3 | R E S U LT S

TH in both peripheral and central nervous systems.

3.1 | Production of TH-over-expressing (TH-HI)
mice

3.3 | TH-HI mice have increased levels of
phosphorylated TH and TH enzymatic activity

Purified BAC DNA containing the murine Th gene was microinjected

Western blot analyses showed an approximate 3-fold increase in the

into the pronucleus of donor oocytes, which were then implanted

optical density of striatal TH phosphorylated at Ser40, Ser31, and

968
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F I G U R E 2 Tyrosine hydroxylase over-expressing mice. (a) Genomic copy number of tyrosine hydroxylase (TH) in TH-HI mice relative
to wild-t ype (WT) littermates. Copy number is determined by comparison of the cycle threshold to that of the reference gene, Tfrc. (n = 5
per group; p ≤ .0001, t-test). (b) Th mRNA levels in TH-HI and WT mice, relative to the reference gene Pkg1. All values are normalized to
dopamine transporter (DAT) mRNA levels in the same sample, which is used as a marker of dopaminergic cells, and shown relative to wild-
type levels (WT n = 8, TH-HI n = 7; p ≤ .0001, t-test with Welch's correction). (c) Midbrain TH and DAT protein expression is shown in adult
mice by western blot together with the loading control, Na-KPase (representative samples) (n = 6 per group). (d) Average optical density of
midbrain TH protein in TH-HI mice (normalized to Na-KPase), shown relative to wild-t ype mice (p = .0003, t-test with Welch's correction).
(e) Average optical density of midbrain DAT protein in TH-HI mice (normalized to Na-KPase), shown relative to wild-t ype mice (p = .34,
t-test). (f) Striatal TH and DAT protein expression is shown in adult mice by western blot together with the loading control, Na-KPase
(representative samples) (n = 6 per group). (g) Average optical density of striatal TH protein in TH-HI mice (normalized to Na-KPase), shown
relative to wild-t ype mice (p ≤ .0001, t-test). (h) Average optical density of striatal DAT protein in TH-HI mice (normalized to Na-KPase),
shown relative to wild-t ype mice (p = .80, t-test). (i) Immunohistochemistry reveals protein expression patterns of TH (red) and DAT (green)
in the midbrain. Yellow represents co-localized TH and DAT. (j) Protein expression patterns of TH (red) and DAT (green) in the striatum.
Yellow represents co-localized TH and DAT. n = number of mice. (p < .001, ***) Mean ± SEM
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Ser19, demonstrating that the level of phosphorylated TH increases

approximately 50% (p ≤ .0001, t-test) (Figure 3b). The total tis-

in proportion to total TH protein levels in transgenic mice (Ser40,

sue content of DOPAC was also elevated by more than 2-fold in

p ≤ .0001, t-test; Fig. S2a, b) (Ser31, p ≤ .0001, t-test; Figure S2d, e)

the TH-H I mice (p ≤ .0001, Mann–W hitney test) (Figure 3c). In

(Ser19, p ≤ .0001, t-test; Figure 2g, h). The proportion of TH that was

addition, DOPAC/dopamine ratios were increased in TH-H I mice

phosphorylated relative to the total pool did not significantly differ

(p ≤ .0001, Mann–W hitney test) (Figure 3d), representative of in-

between wild-t ype and TH-HI mice at any residue (Figure S2c, f, i).

creased dopamine turnover.

Elevated levels of phosphorylated TH in TH-HI mice indicate that
the over-expressed enzyme is in an active state, and in a conformation less susceptible to feedback inhibition by catechols (Daubner
et al. 2011). In turn, the extent of L-DOPA accumulation in striatal

3.5 | VMAT2 levels are unchanged in TH-HI
transgenic mice

samples provides a measure of TH enzymatic activity in vivo (Ferris
et al. 2014). Therefore, we next assessed striatal levels of L-DOPA,

We next sought to determine if the expression of VMAT2 was up-

the direct product of TH. In TH-HI mice, L-DOPA accumulation

regulated in TH-HI mice to accommodate the increased dopamine

following injections of NSD-1015, which blocks aromatic L-amino

production. There was no difference in VMAT2 protein levels be-

acid decarboxylase (AADC), was twice that in wild-t ype animals

tween TH-HI mice and wild-t ype littermates (Figure S3).

(p ≤ .0001, t-test) (Figure 3a). The increase in L-DOPA accumulation
directly shows that the over-expressed TH protein is functional, increasing the rate of dopamine synthesis 2-fold in TH-HI mice.

3.4 | Striatal dopamine levels and tissue dopamine
turnover are increased in TH-HI mice

3.6 | Oxidative stress is enhanced in TH-HI mice
An elevated presence of DOPAC can suggest accelerated ROS production, as H2O2 is produced by MAO during the first steps of dopamine metabolism; in addition, increased levels of DOPAC could
be accompanied by an elevated presence of reactive intermediates

There was a significant effect of genotype on striatal tis-

such as DOPAL, as well as increased reactive species as a result of

sue content of dopamine, which rose over wild-t ype levels by

metabolic oxidation. Concomitant with increased dopamine produc-
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vated in the striatum of TH-HI mice by approximately 30% (p = .031,
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t-test) (Figure 4a). In addition, levels of glutathione—which acts to
neutralize H2O2 —were significantly reduced in the striatum of adult
TH-HI mice (p = .0019, one-way ANOVA), but not in cortical tissue
(Figure 4b, c).
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Wild-t ype mice were treated with reserpine (5 mg/kg) as a
positive control. Reserpine acts by irreversibly blocking VMAT2,

WT TH-HI

in turn inhibiting the transport of catecholamines from the cytosol
to the vesicles, leading to oxidative stress and reduced glutathione
levels (de Freitas et al. 2016; Spina & Cohen, 1989). As expected,

***

reserpine treatment of WT animals results in reduced glutathione
levels (Figure 4b). Importantly, the extent of decrease in glutathione levels of reserpine treated WT animals was similar to the basal

0.10

levels detected in TH-HI (Figure 4b), which is consistent with an

0.05

is observed.

0.00

elevated presence of ROS in regions where increased TH activity

WT TH-HI

F I G U R E 3 Synthesis and tissue content of dopamine and
its metabolites in the striatum of adult mice. TH-HI mice show
elevated tissue content of (a) L-DOPA accumulation following
NSD-1015 injections (WT n = 7, TH-HI n = 7; p ≤ .0001, t-test),
(b) dopamine (DA) (WT n = 10, TH-HI n = 9; p ≤ .0001, t-test), (c)
3,4-dihydroxyphenylacetic acid (DOPAC) (WT n = 10, TH-HI n = 9;
p ≤ .0001, Mann–Whitney test), and (d) DOPAC to DA ratio (WT
n = 10, TH-HI n = 9; p ≤ .0001, Mann–Whitney test). n = number of
mice. (p ≤ .001, ***) Mean ± SEM

3.7 | TH-HI mice have elevated striatal levels of
enzymatic and spontaneous oxidation products
TH-HI mice had elevated striatal levels of the reactive intermediate
metabolite DOPAL compared with wild-t ype mice (p = .010, t-test)
(Figure 4d), resulting from increased enzymatic oxidation. Cysteinyl-
L-DOPA and cysteinyl-dopamine were also elevated in TH-HI animals compared with wild-t ype littermates (p = .0003 and p = .0002,
respectively, t-test) (Figure 4e, f). As an increased presence of
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F I G U R E 4 Markers of oxidative stress in adult TH-HI mice. (a) Concentration of hydrogen peroxide was found to be elevated in striatal
tissue of adult transgenic mice (TH-HI) as compared with wild-t ype (WT) littermates (WT n = 8, TH-HI n = 9)(p = .031, t-test). (b) Total
glutathione levels (GSH) were reduced in striatal tissue of TH-HI mice compared with WT mice. No significant difference in striatal GSH
levels was detected between transgenic mice and WT mice that had been treated with reserpine 120 min prior to dissections (WTres). (WT
n = 14; TH-HI n = 14; WTres n = 7) (all data normalized to WT) (F2, 32 = 7.709, p = .0019, one-way ANOVA, Bonferroni post hoc). (c) No
change in GSH levels was detected in cortical samples. (WT n = 14; TH-HI n = 14; WTres n = 7) (all data normalized to WT) (F2, 33 = 1.647,
p = .21, one-way ANOVA, Bonferroni post hoc). (d) 3,4-dihydroxyphenylacetaldehyde (DOPAL) levels in the striatum of TH-HI mice were
elevated over wild-t ype levels (WT n = 10, TH-HI n = 9)(p = .010, t-test), as were (e) Cysteinylated L-3,4-dihydroxyphenylalanine (Cys-DOPA)
levels (WT n = 10, TH-HI n = 9) (p = .0003, t-test with Welch's correction) and (f) Cysteinylated dopamine (Cys-DA) levels (WT n = 10, TH-HI
n = 9) (p = .0002, t-test). n = number of mice. (p ≤ .05, *; p ≤ .01, **; p ≤ .001, ***) Mean ± SEM

cysteinylated dopamine is considered an indication of accelerated
dopamine auto-oxidation (Chen et al. 2008; Li & Dryhurst, 2001),

3.9 | TH-HI mice have potentiated responses to
amphetamine

these findings demonstrate that increased activity of TH alone is
sufficient to elevate markers of oxidative stress arising from enzy-

The locomotor behaviour of transgenic mice was not found to differ

matic and spontaneous oxidation.

from their wild-t ype littermates when measured for up to 4 hr under
normal (unstimulated) conditions (Figure 5a); similar results were

3.8 | TH-HI mice have increased cardiac levels of
dopamine and its oxidation products

found during baseline recordings prior to an amphetamine challenge
(see minutes 0–60, Figure 5b).
As a functional read-out of enhanced dopamine production
and storage, we challenged mice with two doses of amphetamine

Past studies have suggested that catecholamine dysfunction

(2.0 mg/kg and 3.0 mg/kg). Amphetamine treatment results in mas-

and denervation of the heart may occur early in the pathology of

sive efflux of monoamines through their membrane transporters

Parkinson's disease, preceding the onset of recognizable motor

due to a reversal in the concentration gradient (Heal et al. 2013;

symptoms (Goldstein et al. 2007). To examine whether markers of

Jones et al. 1998; Salahpour et al. 2008; Sulzer et al. 1995). Because

oxidative stress exist in peripheral tissue, we examined catechola-

of its potent effect on the dopaminergic system, amphetamine is

mine content, catecholamine turnover, and cysteinylated catechols

often used to test the integrity of the nigrostriatal pathway, using

in heart tissue. TH-HI mice had increased cardiac concentrations of

locomotor activity as an outcome measure (Giros et al. 1996). When

dopamine (p ≤ .0001, Mann–Whitney test) and DOPAC (p = .0002,

challenged with these two doses of amphetamine (2.0 mg/kg and

Mann–Whitney test). There was a trend towards increased dopa-

3.0 mg/kg), TH-HI mice had a greatly potentiated locomotor re-

mine turnover (p = .054, t-test) (Figure S4a-c). In addition, there was

sponse to amphetamine, more than doubling total distance trav-

a significant increase in Cys-DA (p = .0042, Mann–Whitney test)

elled in the 90 min (Figure 5b, c). In addition, TH-HI mice showed

(Figure 3g). There were no group differences in levels of noradrena-

increased stereotypic behaviour in response to the drug, increasing

line or its metabolite DHPG (Figure S4d–f ). DOPAL was not detected

their stereotypic counts 2-fold following the administration of am-

in any samples of heart tissue.

phetamine at both doses (Figure 5c).
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F I G U R E 5 Locomotor response to amphetamine. (a) Baseline locomotor behaviour over 240 min, measured as total distance travelled
(cm) in 5-min epochs. (Repeated-measures two-way ANOVA: effect of time, F47, 987 = 65.20, p ≤ .0001; effect of genotype, F1,987 = 0.39,
p = .54; genotype x drug interaction, F47, 987 = 1.76, p ≤ .0015; Bonferroni post hoc) (WT n = 12, TH-HI n = 11). (b) Total distance travelled
in 5-min epochs, before and after injection with 3.0 mg/kg amphetamine (arrow denotes time of injection). (Repeated-measures two-way
ANOVA: effect of time, F29,290 = 20.33, p ≤ .0001; effect of genotype, F1,290 = 9.83, p = .011; genotype x drug interaction, F29,290 = 5.49,
p ≤ .0001) (WT n = 6, TH-HI n = 6). (c) Total distance travelled in 90 min after injection of saline (Two-way ANOVA: effect of drug,
F2,39 = 35.36, p ≤ .0001; effect of genotype, F1,39 = 28.45, p ≤ .0001; genotype x drug interaction, F2,39 = 6.625, p = .0033; Bonferroni
post hoc) (saline: WT n = 6, TH-HI n = 6; 2.0 mg/kg: WT n = 13, TH-HI n = 8; 3 mg/kg: WT n = 6, TH-HI n = 6). (d) Total stereotypic counts
in 90 min after injection of saline, 2.0 mg/kg, or 3.0 mg/kg amphetamine (multiple Mann–Whitney tests with the two-stage Benjamini,
Krieger, and Yekutieli procedure) (saline: WT n = 6, TH-HI n = 6; 2.0 mg/kg: WT n = 13, TH-HI n = 8; 3 mg/kg: WT n = 6, TH-HI n = 6). (e)
Quantification of striatal D1 receptors by radioligand binding (n = 4 per group; p = .63, t-test). (f) Quantification of striatal D2 receptors by
radioligand binding (n = 4 per group; p = .99, t-test). n = number of mice. (p ≤ .05, *, p ≤ .01, **; p ≤ .001, ***). Mean ± SEM
The potentiation in amphetamine-induced hyperactivity was not

Tukey's multiple comparisons post hoc t-test). Distance travelled by

associated with alterations in dopamine D1 or D2 receptor levels in

TH-HI mice that had received NSD-1015 was reduced by 97% of the

TH-HI mice (Figure 5e, f).

distance travelled by TH-HI mice that had received the saline pre-
treatment (p < .0001, Tukey's multiple comparisons post hoc t-test)

3.10 | Responses to amphetamine depend on
dopamine synthesis
We next sought to confirm that the elevated amphetamine response

(Figure S5b).

3.11 | TH-HI mice show increased sensitivity to
methamphetamine toxicity

seen in TH-HI mice resulted from de novo dopamine synthesis by
using NSD1015, which blocks AADC. Administration of NDS-1015

We next tested the sensitivity of TH-HI mice to methamphetamine

had a significant drug effect, even during the pre-amphetamine ha-

toxicity. At doses of 5.0 mg/kg or 10 mg/kg, there was no difference

bituation phase (p = .013, two-way ANOVA) (Figure S5a, b). In par-

in the hyperthermic response to methamphetamine between adult

ticular, during this habituation phase, TH-HI mice that had received

TH-HI mice and wild-t ype littermates (Figure 6a). At 48 hr after in-

NSD-1015 demonstrated reduced locomotor activity as compared

traperitoneal injection of 5.0 mg/kg methamphetamine, mean DAT

with those that had received saline (p ≤ .05, Tukey's multiple com-

striatal protein levels were reduced by 62.2% in wild-t ype mice and

parisons post hoc t-test).

67.0% in TH-HI mice relative to saline-treated wild-t ype controls

Wild-t ype and TH-HI mice that had received NSD-1015 did not

(Figure 6b, c). In response to 10 mg/kg, DAT levels were reduced

have a hyperactive response to amphetamine. After receiving an

by 65.2% in wild-t ype mice and 79.7% in TH-HI compared with DAT

amphetamine challenge, total distance travelled by wild-t ype mice

levels of saline-treated wild-t ype mice. The TH-HI group had greater

that had received an NSD-1015 pre-treatment was reduced by 77%

sensitivity to methamphetamine than their wild-t ype littermates at

of that travelled by wild-t ype mice that had received saline (p < .01,

the 10 mg/kg dose (p ≤ .05, two-way ANOVA).
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F I G U R E 6 Toxicity of methamphetamine. (a) Measurements of the core body temperature of animals administered with saline, 5 mg/kg
or 10 mg/kg of methamphetamine revealed no difference in the effect of treatment between genotypes. (p ≤ .05, *; p ≤ .01, **; p ≤ .001, ***,
repeated-measures two-way ANOVA) (WT: saline n = 7, 5 mg/kg n = 7, 10 mg/kg n = 6; TH-HI: saline n = 5, 5 mg/kg n = 7, 10 mg/kg n = 6).
(b) Representative blot, showing striatal DAT protein levels in WT and TH-HI mice, (n = 2 of 4 shown per treatment group). (c) Striatal DAT
protein levels relative to level seen in WT mice treated with saline, after administration of saline, 5 mg/kg or 10 mg/kg methamphetamine.
(effect of genotype, ns; effect of dose, F2, 19 = 255.4, p ≤ .0001; genotype × dose interaction, F2, 19 = 3.59, p = .048; two-way ANOVA)
(Bonferroni post hoc, p = .025, *) n = number of mice. Mean ± SEM

4 | D I S CU S S I O N

have a significant increase in the levels of active-state TH compared
with their non-transgenic littermates, in turn leading to increased

Here we report that directly increasing TH activity in transgenic

dopamine production.

mice augments dopamine turnover and produces markers of oxida-

In TH-HI mice, the proportionate increase in striatal DOPAC

tive stress in the striatum including elevated levels of H2O2, associ-

content exceeded that of dopamine, indicating an increased rate of

ated with accumulation of the autotoxic catecholamine metabolites

intracellular dopamine turnover (Figure 3d) (Gemechu et al. 2018).

DOPAL and Cys-DA. Increased dopamine production also results in

Under normal circumstances, the majority of the catecholamine

increased susceptibility to amphetamine-induced hyperactivity and

pool is stored in vesicles, rendering it available for release upon

methamphetamine toxicity. These findings suggest that a loss of TH

neuronal stimulation and protecting the cell from oxidative pro-

regulation could be one factor contributing to mounting oxidative

cesses that could be damaging (Pifl et al. 2014; Taylor et al. 2014;

stress in early-stage pathologies that is specific to catecholamine

Vernon, 2009). Increased VMAT2 levels have been shown to

neurons.

lead to increased size and filling of presynaptic vesicles (Lohr

TH-HI mice had a 3-fold increase in both mRNA and total TH

et al. 2014, 2015), and thus, an up-regulation in VMAT2 expres-

protein levels (Figure 2c,d, f, g). In addition, transgenic mice had

sion could reflect a strategy by which cells might mitigate damage

approximately 3 times the levels of phosphorylated TH (Figure S2)

induced by an increased presence of monoamines in the cytosol.

and increased rates of TH activity compared with age-matched

TH-HI mice did not differ from wild-t ype littermates in VMAT2

littermates (Figure 3a). Phosphorylation of TH directly influences

levels (Figure S3) and therefore may not have compensated ad-

the rate of catecholamine synthesis by inducing a conformational

equately for the increase in dopamine production. Consistent

change that releases the enzyme from end-product inhibition—a

with this finding, TH-HI mice showed an increase in striatal H2O2

state in which a newly synthesized catechol is bound to ferric (Fe3+)

concomitant with decreased striatal glutathione and increased

iron in the active site of TH following a hydroxylation reaction. In

DOPAL content (Figure 4).

turn, unbinding of catechols allows the iron molecule to be reduced

A recent study by Bucher et al. (2020) that examined the crit-

to its ferrous (Fe2+) form, returning TH to an active state and free-

ical role of VMAT2 in maintaining dopamine homeostasis further

ing the iron molecule for further interactions (Dunkley et al. 1996;

emphasizes the toxicity of rising levels of cytosolic dopamine. An

Haavik, 1997; Haavik et al. 1997). Our findings show that TH-HI mice

adeno-associated virus was used to introduce small-hairpin RNA
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interference of endogenous VMAT2 in adult rats, resulting in a pro-

causally linked lysosomal dysfunction and α-synuclein accumu-

gressive adult-onset loss of VMAT2 and accumulation of unseques-

lation to elevated levels of oxidized dopamine in the cytosol, in a

tered dopamine. The disruption resulted in a subsequent increase

dopamine-dependent "toxic cascade," using dopamine neurons de-

in dopamine metabolism, behavioural deficits and degeneration of

rived from Parkinson's patients (Burbulla et al. 2017). In cultured

nigrostriatal neurons—consequences that were rescued through the

human oligodendrocytes and PC12 rat pheochromocytoma cells,

reintroduction of VMAT2 (Bucher et al. 2020). These results show

Jinsmaa et al. demonstrated that DOPAL is even more potent than

that dysregulation of dopamine homeostasis acquired in adulthood

dopamine in producing quinones and protein modifications, includ-

is sufficient to produce dopamine toxicity in the nigrostriatal path-

ing the oligomerization of α-synuclein. Notably, treatment with the

way (Bucher et al. 2020).

antioxidant N-acetylcysteine—a precursor of glutathione— reduced

Dopamine dysregulation can promote cytotoxicity due to

DOPAL-quinone formation, in turn attenuating or preventing all as-

the potential for oxidation (Caudle et al. 2007; Chen et al. 2008;

sociated protein modifications (including α-synuclein oligomeriza-

Hastings et al. 1996; Masoud et al. 2015; Mosharov et al. 2009;

tion) (Jinsmaa et al. 2018).

Taylor et al. ,2009, 2014). DOPAL and H2O2 are formed as a result

TH-HI mice also showed an increase in the hyperactive response

of the enzymatic metabolism of dopamine (Goldstein et al. 2013;

to amphetamine (Figure 5). This response was dependent on de novo

Spina & Cohen, 1989). DOPAL itself also spontaneously oxidizes

dopamine synthesis (Supp. Figure 5). Amphetamine releases dopa-

forming DOPAL-quinones, and in the process generates superox-

mine from vesicles and causes a rapid efflux of cytosolic dopamine

ide radicals. These radicals are believed to contribute to DOPAL-

into the extracellular space due to backward transport through the

induced oligomerization of α-s ynuclein (Werner-A llen et al. 2017),

cell membrane dopamine transporter (Masoud et al. 2015; Takahashi

impede vesicular functions (Plotegher et al. 2017), and damage

et al. 1997). Similarly, methamphetamine can redistribute dopamine

mitochondrial function (Sarafian et al. 2019). DOPAL-quinones are

from intraneuronal storage sites and in this way is believed to result

capable of forming protein adducts with α-s ynuclein and other in-

in increased dopamine auto-oxidation and dopamine terminal injury

tracellular proteins, which can in turn initiate cytotoxic processes

(Fumagalli et al. 1998). Our finding that TH-HI mice had augmented

(Jinsmaa et al. 2018).

sensitivity to methamphetamine toxicity is consistent with an ad-

In addition to producing damaging compounds through the
process of metabolism, unsequestered dopamine and related com-

ditive effect on an already-elevated basal state of oxidative stress
(Figure 6).

pounds are susceptible to spontaneous oxidation, forming ROS

How an increase in TH activity might specifically contribute to

and dopamine-quinones. Dopamine-quinones—which are electron-

oxidative stress in vivo is of particular relevance, as past studies

deficient—can then react with reduced sulfhydryl groups such as

have shown diminished TH regulation to coincide with other patho-

free cysteine or glutathione, or covalently bind to cysteine groups

logical change, such as increased α-synuclein aggregation (Alerte

on nucleophilic proteins (often at the active site), which can impair

et al. 2008; Farrell et al. 2014; Greenwood et al. 1991; Liu et al. 2015;

their function and have detrimental effects on the cell (Goldstein

Liu, Zhang, et al., 2008; Locke et al. 2008; Lou et al. 2010; Walker

et al. 2016, 2017; Hastings et al. 1996; Hastings & Zigmond, 1994).

et al. 2013; Zhou et al. 2011). Although Parkinson's disease and

Therefore, the presence of cysteinylated catechols is used as a mea-

ageing are associated with dopaminergic cell loss—and thus, a loss

sure of the oxidation of free cytosolic dopamine (Caudle et al. 2007;

of TH-positive cells—past studies showed that in C57BL mice aged

Chen et al. 2008; Masoud et al. 2015). TH-HI mice had elevated lev-

104 weeks, striatal DA and DOPAC contents were 5–7 times higher

els of DOPAL as well as increased levels of cysteinyl-L-DOPA and

in surviving TH-positive substantia nigra pars compacta neurons

cysteinyl-dopamine (Figure 4), providing evidence of both enzymatic

compared with those in 8-week-old mice, suggesting that surviving

and spontaneous oxidation (Figure S6) (Chen et al. 2008; Fornstedt

neurons compensate for the neuronal loss by increasing dopamine

et al. 1989, 1990; Fornstedt & Carlsson, 1989; Hastings et al. 1996).

synthesis (Greenwood et al. 1991). Similar results have been seen in

Recent studies suggest a critical link between unsequestered

MPTP-treated mice, where there is a compensatory increase in TH

catecholamines and α-synuclein aggregation, leading to toxicity.

activity in the remaining individual surviving neurons (Greenwood

Alpha-synuclein oligomers have been shown to be kinetically sta-

et al. 1991; Kozina et al. 2014). Therefore, particularly as other pa-

bilized by oxidized dopamine and other catecholamines in vitro

thologies emerge, it is possible that TH might contribute to mounting

(Conway et al. 2001; Mor et al. 2017; Norris & Giasson, 2005;

oxidative stress if activity is considered at the level of the cell.

Norris et al. 2005). Mor et al. (2017) reported that chronic eleva-

TH-HI mice may be a useful model for further investigating

tion of dopamine levels in α-synuclein A53T mice results in pro-

catecholamine autotoxicity in the context of Parkinson's disease,

gressive nigrostriatal degeneration and locomotor impairment, to

particularly as it relates to α-synuclein modifications and dopami-

an extent not seen in A53T mice alone, demonstrating a synergistic

nergic cell death. First, oxidation products are known to stabilize

toxicity of dopamine and α-synuclein. Dopamine was also shown

α-synuclein oligomers (Conway et al. 2001; Mor et al. 2017), which

to modify α-synuclein aggregation in vivo, forming oligomers that

have a diminished ability to regulate TH activity (Hua et al. 2015;

share biochemical and structural characteristics with neurotoxic

Lou et al. 2010; Park et al. 2016; Peng et al. 2005; Wu et al. 2011).

α-synuclein oligomers produced by interactions with dopamine

Therefore, it is possible that the products of spontaneous and

in vitro (Mor et al. 2017). In another study, Burbulla et al. (2017)

metabolically oxidized dopamine in turn impede the regulation of
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dopamine production, producing a pathogenic cycle that further
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